We are a clinical-stage company developing therapeutic antibodies for inhibitory receptors on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases
Our lead drug candidate is antolimab (AK002), an investigational antibody that targets Siglec-8, an inhibitory receptor selectively found on mast cells and eosinophils. In clinical and preclinical studies, antolimab has been shown to...
We are a clinical-stage company developing therapeutic antibodies for inhibitory receptors on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases
Our lead drug candidate is antolimab (AK002), an investigational antibody that targets Siglec-8, an inhibitory receptor selectively found on mast cells and eosinophils. In clinical and preclinical studies, antolimab has been shown to broadly inhibit mast cells and rapidly deplete eosinophils.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.